PureTech Health plc (PTCHF)
OTCMKTS · Delayed Price · Currency is USD
1.650
0.00 (0.00%)
May 12, 2025, 4:00 PM EDT

PureTech Health Company Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.

It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions.

In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers.

Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease.

The company was incorporated in 2015 and is based in Boston, Massachusetts.

PureTech Health plc
PureTech Health logo
Country United Kingdom
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 80
CEO Bharatt Chowrira

Contact Details

Address:
6 Tide Street
Boston, 02210
United States
Phone 617 482 2333
Website puretechhealth.com

Stock Details

Ticker Symbol PTCHF
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number GB00BY2Z0H74
SIC Code 2836

Key Executives

Name Position
Dr. Bharatt M. Chowrira J.D., Ph.D. Chief Executive Officer and Executive Director
Daphne Zohar Founder, Senior Advisor and Board Observer
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder and Non-Executive Director
Dr. Eric Elenko Ph.D. Co-Founder and President
Dr. David R. Elmaleh Ph.D. Co-Founder and Senior Advisor
Lauren A. White M.B.A. Chief Financial Officer
Allison Mead Talbot Senior Vice President of Communications and Head of Investor Relations
Charles Sherwood III, J.D., Ph.D. General Counsel and Company Secretary
Spencer Ball Executive Vice President of Human Resources
Aleksandra Filipovic M.D., Ph.D. Head of Oncology